Allen K Barriers to treatment for addicted African-American women. J Natl Med Assoc. 1995 Oct;87(10):751-6.
Ashery RS, Carlson RG, Falck RS, Siegal HA Injection drug users, crack-cocaine users, and human services utilization: an exploratory study. Soc Work. 1995 Jan;40(1):75-82.
Baron RM, Kenny DA The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986 Dec;51(6):1173-82.
Battjes RJ, Onken LS, Delany PJ Drug abuse treatment entry and engagement: report of a meeting on treatment readiness. J Clin Psychol. 1999 May;55(5):643-57.
Burton P, Gurrin L, Sly P Extending the simple linear regression model to account for correlated responses: an introduction to generalized estimating equations and multi-level mixed modelling. Stat Med. 1998 Jun 15;17(11):1261-91.
De Leon G, Melnick G, Kressel D, Jainchill N Circumstances, motivation, readiness, and suitability (the CMRS scales): predicting retention in therapeutic community treatment. Am J Drug Alcohol Abuse. 1994 Nov;20(4):495-515.
Farabee D, Rawson R, McCann M Adoption of drug avoidance activities among patients in contingency management and cognitive-behavioral treatments. J Subst Abuse Treat. 2002 Dec;23(4):343-50.
Fischer B, Chin AT, Kuo I, Kirst M, Vlahov D Canadian illicit opiate users' views on methadone and other opiate prescription treatment: an exploratory qualitative study. Subst Use Misuse. 2002 Mar;37(4):495-522.
Fitzgerald JL, Mulford HA An experimental test of telephone aftercare contacts with alcoholics. J Stud Alcohol. 1985 Sep;46(5):418-24.
Fortney JC, Booth BM, Blow FC, Bunn JY The effects of travel barriers and age on the utilization of alcoholism treatment aftercare. Am J Drug Alcohol Abuse. 1995 Aug;21(3):391-406.
Iguchi MY, Belding MA, Morral AR, Lamb RJ, Husband SD Reinforcing operants other than abstinence in drug abuse treatment: an effective alternative for reducing drug use. J Consult Clin Psychol. 1997 Jun;65(3):421-8.
Intagliata J A telephone follow-up procedure for increasing the effectiveness of a treatment program for alcoholics. J Stud Alcohol. 1976 Sep;37(9):1330-5.
Karno MP, Beutler LE, Harwood TM Interactions between psychotherapy procedures and patient attributes that predict alcohol treatment effectiveness: a preliminary report. Addict Behav. 2002 Sep-Oct;27(5):779-97.
Koumans AJ, Muller JJ, Miller CF Use of telephone calls to increase motivation for treatment in alcoholics. Psychol Rep. 1967 Aug;21(1):327-8.
Lash SJ, Blosser SL Increasing adherence to substance abuse aftercare group therapy. J Subst Abuse Treat. 1999 Jan;16(1):55-60.
Lash SJ, Dillard W Encouraging participation in aftercare group therapy among substance-dependent men. Psychol Rep. 1996 Oct;79(2):585-6.
McKay JR Effectiveness of continuing care interventions for substance abusers. Implications for the study of long-term treatment effects. Eval Rev. 2001 Apr;25(2):211-32. Review.
Ouimette PC, Moos RH, Finney JW Influence of outpatient treatment and 12-step group involvement on one-year substance abuse treatment outcomes. J Stud Alcohol. 1998 Sep;59(5):513-22.
Pan W Sample size and power calculations with correlated binary data. Control Clin Trials. 2001 Jun;22(3):211-27.
Richter KP, Bammer G A hierarchy of strategies heroin-using mothers employ to reduce harm to their children. J Subst Abuse Treat. 2000 Dec;19(4):403-13.
Rochon J Application of GEE procedures for sample size calculations in repeated measures experiments. Stat Med. 1998 Jul 30;17(14):1643-58.
Spitzer RL, Williams JB, Gibbon M, First MB The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry. 1992 Aug;49(8):624-9.
Stahler GJ, Cohen E Using ethnographic methodology in substance abuse treatment outcome research. J Subst Abuse Treat. 2000 Jan;18(1):1-8.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
